Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 12
2003 20
2004 16
2005 29
2006 44
2007 44
2008 49
2009 69
2010 84
2011 97
2012 96
2013 125
2014 136
2015 168
2016 173
2017 188
2018 199
2019 252
2020 326
2021 377
2022 396
2023 339
2024 404
2025 424
2026 366
2027 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,995 results

Results by year

Filters applied: . Clear all
Page 1
Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
Le X, Kim TM, Loong HH, Prelaj A, Goh BC, Li L, Fang Y, Lu S, Dong X, Wu L, Shinno Y, Daniele G, Yang TY, Kim HR, Ruiter G, Zhao J, Novello S, Miao L, Jänne PA, Goto K, Rüttinger D, Descamps T, Brase JC, Bao W, Li R, Brega N, Grassi P, Girard N, Tan DS; SOHO-01 Investigators. Le X, et al. Among authors: zhao j. N Engl J Med. 2025 Nov 6;393(18):1819-1832. doi: 10.1056/NEJMoa2511065. Epub 2025 Oct 17. N Engl J Med. 2025. PMID: 41104928 Clinical Trial.
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.
Shitara K, Elimova E, Liu T, Tabernero J, Lee KW, Schenker M, Tebbutt NC, Ajani J, Salimin N, Ku G, Gwang Kim J, Ales Diaz I, Zhang J, Pietrantonio F, Bai LY, Le Sourd S, Zhao J, Hierro C, Kiberu A, Van Herpe F, Bao Y, Zhang H, Yang L, Li V, Gartner EM, Chen Y, Grim J, Rha SY, Shen L; HERIZON-GEA-01 Investigators. Shitara K, et al. Among authors: zhao j. N Engl J Med. 2026 May 28;394(20):2002-2014. doi: 10.1056/NEJMoa2517729. N Engl J Med. 2026. PMID: 42202319 Clinical Trial.
Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Yue D, Huang M, Song P, Chen Y, Li B, Fu J, Guo J, Cheng C, Chen Q, Xu S, Liu H, Lv F, Hu J, Jiang K, Mao W, Shen B, Ye F, Li J, Zhang X, Guo S, Yu B, Zhu Y, Wu M, Zheng W, Chen F, He Z, Bai Y, Xin H, Chen K, Mao N, Zhang Y, Wang B, Zhang L, Chen X, Mei X, Miao L, Wang R, Li G, Yao J, Zhao J, Chen C, Liu J, Wei L, Yan X, Jin B, Liu X, Liu Z, Tian H, Xing W, Yang L, Ge D, Li X, Li S, Song Y, Zang A, Zhang D, Zhuang W, Liu Z, Yuan X, Fu T, Shen Z, Zhang X, Cao Q, Zhao L, Mao L, Ding L, Lu Y, Wang C; ELEVATE Study Group. Yue D, et al. Among authors: zhao j. N Engl J Med. 2026 Jul 9;395(2):151-161. doi: 10.1056/NEJMoa2518990. N Engl J Med. 2026. PMID: 42418775 Clinical Trial.
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer.
Liao J, Yao W, Yu Y, Li A, Huang J, Li X, Sun L, Zhang Y, Wang Y, Qu X, Zhao J, Wang H, Zhuang W, Hu L, Chen X, Pang L, Yang M, Chen Z, Zhang Y, Li T, Yu W, Zeng Y, Li J, Kataria R, Blumenthal G, Akala O, Liu Y, Shen Y, Ge J, Hong S, Yang Y, Zhang L, Fang W. Liao J, et al. Among authors: zhao j. Cancer Cell. 2026 Jul 13;44(7):1401-1417.e9. doi: 10.1016/j.ccell.2026.05.020. Epub 2026 Jun 18. Cancer Cell. 2026. PMID: 42314664
High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial.
Yu J, Jiang L, Zhao L, Yang X, Wang X, Yang D, Zhuo M, Chen H, Huang W, Zhu Z, Zhang M, Song Y, Li Q, Ma Z, Wang Q, Qu Y, Yu R, Yu H, Zhao J, Shi A; Trial Management Group. Yu J, et al. Among authors: zhao j. Lancet Respir Med. 2024 Oct;12(10):799-809. doi: 10.1016/S2213-2600(24)00189-9. Epub 2024 Aug 12. Lancet Respir Med. 2024. PMID: 39146944 Clinical Trial.
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.
Duan JC, Zhong J, Sun BY, Zhao WH, Wu L, Fei KL, Chu Q, Guo QS, Song QB, Yu Y, Zhu DX, Liu XY, Zhao J, Zhan ZX, Li S, Nie L, Lin J, Peng XD, Zhong DS, Zhou J, Li LH, Chen YF, Hu C, Mok T, Wang ZJ, Wang J. Duan JC, et al. Among authors: zhao j. CA Cancer J Clin. 2026 Mar-Apr;76(2):e70071. doi: 10.3322/caac.70071. CA Cancer J Clin. 2026. PMID: 41818162 Free PMC article. Clinical Trial.
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Wang J, et al. Among authors: zhao j. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.
3,995 results